Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464723 · ClinicalTrials.gov registry record · Phase 4
Study EvAluating Genotypes While Using Lucentis 2
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT01464723 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 66 participants.
The verdict
NCT01464723, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464723
The ClinicalTrials.gov registry entry for NCT01464723 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01464723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464723 about?
NCT01464723 is a clinical study titled "Study EvAluating Genotypes While Using Lucentis 2". The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
What is the current status of trial NCT01464723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2008-05. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01464723?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01464723?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.